Lipoptena grahami Bequaert, 1942 (Diptera, Hippoboscidae) was first described in China almost 80 years ago. Species of Lipoptena were obligate blooding-feeding insects and commonly reported as vectors of wild animals of Cervinae. The complete mitochondrial genome of L. grahami was assembled to 16,953 bp in length. The AT content of L. grahami mitogenome is 80.59%. In total, 22 tRNAs, 2 rRNAs, and 13 protein-coding genes (PCGs) were annotated from L. grahami ’s mitogenome. The typical clover-leaf structure of tRNAs was also analyzed and confirmed except the tRNA-Ser (AGN). A phylogenetic tree was constructed based on L. grahami with some other fly species.

Background: Human CD133 + hematopoietic progenitor cells (HPCs) are a specific subset of cells and can regulate the malignancy of tumors. However, how CD133 + HPCs affect the malignancy of human breast cancer has not been clarified.Methods: The CD133 + HPCs were isolated and purified from human umbilical cord blood (UCB) .We used in vitro culture of the MCF-7 and MDA-MB-231 cell line, and MCF-7 and MDA-MB-231 cells into nude mice in order to tested whether CD133 + HPCs affected the apoptosis, proliferation, invasion and EMT of breast cancer cells.Results: Co-culture with CD133 + HPCs, but not UCB CD133- cells, promoted the proliferation of human breast cancer MCF-7 or MDA-MB-231 cells, accompanied by reducing their spontaneous apoptosis in vitro and co-administration with CD133 + HPCs significantly enhanced the growth of implanted breast cancer in vivo. Furthermore, co-culture with CD133 + HPCs, enhanced the invasion of breast cancer cells, N-cadherin and Vimentin expression, but reduced E-cadherin expression in Breast cancer cells.Conclusions: The data indicated that CD133 + HPCs enhanced the malignancy of breast cancer cells by inhibiting their spontaneous apoptosis and promoting the process of epithelial mesenchymal transition. These findings may provide new insights in the role of human CD133 + HPCs in the pathogenic process of breast cancer. Therefore, CD133 + HPCs may be a new therapeutic target for inhibiting the progression of breast cancer.